Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ScripsAmerica has signed a development, manufacturing and supply deal with Capricorn Pharma (CPI) for RapiMed children's pain and fever reliever.
Subscribe to our email newsletter
Formulated in cherry and grape flavors, RapiMed dissolvable pain relief remedy 80mg and 160mg tablets will be manufactured and distributed by CPI within the US and North America.
ScripsAmerica chief executive officer Bob Schneiderman said, "CPI is a very reputable manufacturer in the generic drug market and we are confident that our relationship will be very productive and beneficial for ScripsAmerica and its shareholders."
The contract has a two-year base performance period and includes options that extend to five years.
As per the deal, a minimum of 20 million tablets will be manufactured and distributed by CPI with anticipated increase in production every year.
RapiMed is scheduled to launch into retail, food and drug store chains in September 2013.